丰原药业(000153) - 2018 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2018 was ¥712,890,808.20, representing a 35.52% increase compared to ¥526,057,989.33 in the same period last year[10] - The net profit attributable to shareholders for Q1 2018 was ¥11,441,363.39, up 22.12% from ¥9,368,728.40 in the previous year[10] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥10,385,439.78, reflecting a 43.40% increase from ¥7,242,500.00 year-on-year[10] - The net cash flow from operating activities for Q1 2018 was ¥16,564,706.33, which is a 21.32% increase compared to ¥13,654,050.92 in the same period last year[10] - Basic earnings per share for Q1 2018 were ¥0.0361, a 20.33% increase from ¥0.0300 in the previous year[10] Assets and Shareholder Equity - Total assets at the end of Q1 2018 were ¥2,816,793,334.05, up 1.77% from ¥2,767,714,922.77 at the end of the previous year[10] - The net assets attributable to shareholders at the end of Q1 2018 were ¥1,218,468,380.45, a slight decrease of 0.16% from ¥1,220,456,400.86 at the end of the previous year[10] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 34,906[14] - The top three shareholders, all state-owned enterprises, held a combined 25.12% of the company's shares[14] Revenue and Expenses - Operating revenue increased by 35.52% to RMB 712,890,808.20 compared to RMB 526,057,989.33 in the same period last year, primarily due to enhanced market expansion and increased pharmaceutical sales[19] - Sales expenses surged by 103.29% to RMB 152,666,314.10, reflecting higher market expansion costs due to increased sales revenue[19] - Tax expenses increased by 48.19% to RMB 9,359,920.68, driven by the rise in operating income[19] - Income tax expenses rose by 72.23% to RMB 9,749,147.97, reflecting an increase in total profit compared to the previous year[19] Cash Flow and Financing - The net cash flow from financing activities improved by 50.47%, decreasing to RMB -10,963,799.57 from RMB -22,135,232.06, indicating reduced cash outflow for debt repayment[19] Asset Management - Prepayments rose by 30.53% to RMB 75,163,750.32 from RMB 57,584,852.11, attributed to increased advance payments to suppliers[19] - Other current assets decreased by 38.76% to RMB 5,080,272.24 from RMB 8,296,103.36, mainly due to a reduction in input VAT credits[19] - Asset impairment losses decreased significantly by 97.83% to RMB 44,612.18, due to a reduction in bad debt provisions[19] - The fair value change income turned negative at RMB -135,950.18, a decline of 106.70% compared to a gain of RMB 2,029,725.86 in the previous year[19] - The company reported an asset disposal gain of RMB 390,810.38, marking a 100% increase compared to the previous year[19] Investments - The company reported a total investment of 13,730,620.48 CNY in securities, with a year-end value of 13,385,770.30 CNY, resulting in a loss of 80,079.49 CNY during the reporting period[23] - The company holds 1,000,000 shares of Jingsheng Intelligent, with an initial investment of 7,491,437.63 CNY and a current value of 7,470,000.00 CNY, reflecting a loss of 4,361.76 CNY[23] - The company has no derivative investments during the reporting period[24] Compliance and Governance - There were no research, communication, or interview activities conducted during the reporting period[25] - The company reported no violations regarding external guarantees during the reporting period[26] - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[27]